Health Care • Medical/Dental Instruments
$5.27 ▲ +0.00
(0.00%)
MKT CAP: $45.3M • VOL: 14.7K
52W L $4 52W H $36
ROARABLE / RQD
D+ • 53/100
PIOTROSKI
7 / 9
SNWV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $44.1M | $32.3M | $19.3M |
| YoY Revenue Growth % | +36.3% | +67.9% | — |
| Gross Profit | $34.0M | $24.6M | — |
| Gross Margin % | 77.1% | 75.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $4.9M | $3.8M | -$540.0K |
| Operating Margin % | 11.2% | 11.9% | -2.8% |
| Net Income (GAAP) | $11.8M | -$33.1M | -$25.8M |
| EBITDA (Normalized) | $6.5M | $4.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.9M | $2.5M | -$4.5M |
| Capital Expenditures (CapEx) | $1.9M | $490.0K | — |
| Free Cash Flow (FCF) | $1.9M | $2.0M | -$4.5M |
| FCF Margin % | 4.4% | 6.1% | -23.6% |
| Return on Invested Capital (ROIC %) | 67.3% | 95.0% | — |
| Cash & Short-Term Equivalents | $12.0M | $10.2M | — |
| Total Debt (Short + Long Term) | $16.1M | — | — |
| Total Stockholders' Equity | $1.6M | -$15.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SNWV.